Login / Signup

Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus.

Richard A FurieRonald F van VollenhovenKenneth KalunianSandra NavarraJuanita Romero-DiazVictoria P WerthXiaobi HuangGeorge ClarkHua CarrollAdam MeyersCristina MusselliCatherine BarbeyNathalie Franchimontnull null
Published in: The New England journal of medicine (2022)
In a phase 2 trial involving participants with SLE, litifilimab was associated with a greater reduction from baseline in the number of swollen and tender joints than placebo over a period of 24 weeks. Longer and larger trials are required to determine the safety and efficacy of litifilimab for the treatment of SLE. (Funded by Biogen; LILAC ClinicalTrials.gov number, NCT02847598.).
Keyphrases
  • systemic lupus erythematosus
  • disease activity
  • phase iii
  • clinical trial
  • study protocol
  • randomized controlled trial
  • phase ii
  • double blind
  • smoking cessation